3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
11
Obesity
4
Sarcopenia
3
Polycystic Ovary Syndrome
3
Neoplasms
3
Melanoma
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Malnutrition
2
Lymphoma, Follicular
2
Colorectal Neoplasms
2
Breast Carcinoma In Situ
2
Wound Infection
1
Weight Loss
1
Urinary Bladder Neoplasms
1
Surgical Wound Infection
1
Stomach Neoplasms
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Psoriasis
1
Precancerous Conditions
1
Postoperative Complications
1
Polyps
1
Phagocyte Bactericidal Dysfunction
1
Pain
1
Paget's Disease, Mammary
1
Overweight
1
Osteoarthritis
1
Olfaction Disorders
1
Non-alcoholic Fatty Liver Disease
1
Interventions
telitacicept
3
fludarabine
3
Prednisone
3
Cyclophosphamide
3
Specimen Handling
2
Nivolumab
2
Antilymphocyte Serum
2
thymoglobulin
1
remdesivir
1
prednylidene
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
cabozantinib
1
Vitamin D
1
Valsartan
1
Pyridostigmine Bromide
1
Population Groups
1
Platinum Compounds
1
Plasma Exchange
1
Peripheral Blood Stem Cell Transplantation
1
Music Therapy
1
Melphalan
1
Ipilimumab
1
Infliximab
1
Immunoglobulins, Intravenous
1
Hydroxychloroquine
1
Fish Oils
1
Fatty Acids, Omega-3
1
Etoposide
1
Etanercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Autoimmune Diseases
×
Docosahexaenoic Acids
×
Clear all
NCT01351805
2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA
Completed
25,871 enrolled
15 charts